AstraZeneca PLC (AZN)vsSight Sciences Inc (SGHT)
AZN
AstraZeneca PLC
$157.70
-0.51%
HEALTHCARE · Cap: $257.57B
SGHT
Sight Sciences Inc
$8.53
-5.54%
HEALTHCARE · Cap: $491.94M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 73501% more annual revenue ($61.37B vs $83.38M). AZN leads profitability with a 17.0% profit margin vs -35.7%. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
SGHT
Avoid25
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+19.4%
Fair Value
$195.54
Current Price
$157.70
$37.84 discount
Margin of Safety
+30.4%
Fair Value
$7.94
Current Price
$8.53
$0.59 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
19.5% revenue growth
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
Trading at 8.8x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -56.3% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.19 suggests the stock is reasonably priced for its growth.
Bull Case : SGHT
The strongest argument for SGHT centers on Revenue Growth. Revenue growth of 19.5% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : SGHT
The primary concerns for SGHT are Price/Book, EPS Growth, Market Cap.
Key Dynamics to Monitor
AZN profiles as a mature stock while SGHT is a growth play — different risk/reward profiles.
SGHT carries more volatility with a beta of 2.50 — expect wider price swings.
SGHT is growing revenue faster at 19.5% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 25/100), backed by strong 17.0% margins. SGHT offers better value entry with a 30.4% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Sight Sciences Inc
HEALTHCARE · MEDICAL DEVICES · USA
Sight Sciences Inc. (SGHT) is an innovative medical technology company specializing in the advancement of treatments for ocular diseases, with a particular emphasis on glaucoma management through both surgical and non-surgical approaches. The company’s diverse product portfolio, supported by a robust intellectual property framework, positions it favorably as demand for minimally invasive ophthalmic therapies escalates. By focusing on enhancing patient outcomes and refining its distribution network, Sight Sciences is set to capture significant market share in the evolving healthcare landscape, making it a noteworthy opportunity for institutional investors seeking growth in the medical technology sector.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?